PL02.3.A NRG ONCOLOGY STUDY BN007: RANDOMIZED PHASE II/III TRIAL OF IPILIMIUMAB (IPI) PLUS NIVOLUMAB (NIVO) VS. TEMOZOLOMIDE (TMZ) IN MGMT-UNMETHYLATED (UMGMT) NEWLY DIAGNOSED GLIOBLASTOMA (NGBM)
PL02.3.A NRG 肿瘤学研究 BN007:伊匹木单抗 (IPI) 联合纳武利尤单抗 (NIVO) 与替莫唑胺 (TMZ) 治疗 MGMT 非甲基化 (UMGMT) 新诊断胶质母细胞瘤 (NGBM) 的随机 II/III 期试验
期刊:Nucleic Acids Research
影响因子:13.1
doi:10.1093/nar/gkad629
Douaihy, Maria; Topno, Rachel; Lagha, Mounia; Bertrand, Edouard; Radulescu, Ovidiu; Lassman, A B; Polley, M C; Iwamoto, F M; Sloan, A E; Wang, T J C; Aldape, K D; Wefel, J S; Gondi, V; Gutierrez, A N; Manasawala, M; Gilbert, M R; Sulman, E P; Wolchok, J D; Greene, R M; Neil, E C; Lukas, R V; Goldlust, S A; Snuderl, M; Dignam, J J; Won, M; Movsas, B; Mehta, M P